60

Jiangsu Lianhuan Pharmaceutical Co Ltd

600513 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

12.49CNY-0.44 (-3.40%)

Price History

Full chart

Market Stats

Previous Close12.93
Open13.08
Day Range12.45 – 13.10
52-Week Range13.67 – 32.27
Volume5.66M
Market Cap4.31B
P/E (TTM)0.00
Forward P/E40.32
EPS-0.16
Dividend Yield0.46%
Beta-0.23
50-Day Avg16.14
200-Day Avg18.90

About

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, dapoxetine hydrochloride, milrinone injection, aprilite, ebastine tablets, felodipine tablets, tadalafil, and betasine besylate tablets, as well as danazol suppositories, drapavelin hydrochloride injection, and terfenadine tablets. It also provides urinary system drugs, including eprepitant tablets, terazosin tablets, and drotaverine hydrochloride injections; antihistamines comprising terfenadine, and cetirizine hydrochloride tablets; cardiovascular drugs that include felodipine, simvastatin, and amlodipine maleate tablets; steroid hormones, which consist of prazosinone sulfate sodium for injection and danazol capsules; and antibiotics, such as oxithromycin capsules. In addition, the company offers API products, such as hydrocortisone, hydrocortisone acetate, levonorgestrel, dexamethasone sodium phosphate, dexamethasone acetate, tazarotene, saxagliptin monohydrate, sacubitril valsartan sodium, adapalene, milrinone, phentolamine mesylate, terfenadine, aminomethylbenzoic acid, lumbrokinase, chloramphenicol, balofoxacin, fludrocortisone acetate, relugolix, bilastine, crisaborole, argatroban, hexyl aminolevulinate hydrochloride, finerenone, enarodustat, dotinurad, methylprednisolone succinate, hydrocortisone sodium succinate, arotinolol hydrochloride, darlotamide, adapalene, triamcinolone acetonide acetate, baloxavir marboxil, acetoacetate methylprednisolone, vericiguat, and pemafibrate. Further, it engages in the wholesale of chemical raw materials and pharmaceuticals, as well as the sale of medical equipment and electronic products. The company exports its products. Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 1999 and is based in Yangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Zhen Hua Qian
  • Employees2.13K
  • HeadquartersNo. 9, Jiankang 1st Road, Yangzhou, China, 225127, China
  • Websitehttps://www.lhpharma.com

Leadership

  • Mr. Zhen Hua QianChairman & Secretary of the Board · b. 1971
  • Mr. Ben NiuGM & Director · b. 1981
  • Mr. Hao XueFinancial Director · b. 1990
  • Mr. Liang Sheng ZhouChief Engineer · b. 1970
  • Mr. Qing Song ChuDeputy General Manager · b. 1971
  • Mr. Yi ShenDeputy General Manager · b. 1966
  • Mr. Zhang Kun HuDeputy General Manager · b. 1971
  • Ting Ting MaAccounting Supervisor
  • Mr. Zhou JunDeputy General Manager · b. 1970
  • Mr. Yong Jun ZhuDeputy General Manager · b. 1968

Financials

Income Statement

Currency: CNY2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Revenue64.69M69.25M78.51M112.34M181.19M172.99M166.24M194.78M225.37M259.89M289.44M324.21M571.88M623.30M668.69M642.43M604.86M689.10M1.02B1.29B1.39B1.65B1.96B2.17B2.16B
Growth (%)-+7.03%+13.38%+43.09%+61.29%-4.53%-3.90%+17.17%+15.70%+15.32%+11.37%+12.01%+76.39%+8.99%+7.28%-3.93%-5.85%+13.93%+47.91%+26.60%+7.42%+18.74%+18.80%+11.20%-0.63%
Cost of Revenue33.09M28.78M31.04M65.45M114.10M98.30M86.72M103.20M117.80M133.26M148.55M163.00M325.10M334.43M321.00M276.82M251.23M214.58M320.48M515.15M641.29M748.86M912.62M1.13B1.10B
Gross Profit31.60M40.47M47.47M46.88M67.09M74.70M79.52M91.58M107.57M126.63M140.90M161.21M246.78M288.87M347.68M365.62M353.63M474.52M698.75M775.18M744.75M896.95M1.04B1.04B1.06B
Gross Margin48.85%58.44%60.46%41.73%37.03%43.18%47.83%47.02%47.73%48.73%48.68%49.72%43.15%46.35%51.99%56.91%58.46%68.86%68.56%60.08%53.73%54.50%53.32%48.02%49.13%
Operating Expense16.40M19.93M23.30M28.36M54.14M62.67M65.74M83.52M95.51M107.31M116.97M131.81M200.62M242.26M293.97M306.68M277.02M384.10M610.15M673.41M601.54M740.72M855.49M869.23M930.48M
Operating Income15.20M20.53M24.16M18.52M12.95M12.03M13.78M8.06M12.06M19.32M23.93M29.40M46.17M46.61M53.71M58.93M76.61M90.42M88.60M101.77M143.21M156.23M187.05M174.77M131.02M
Operating Margin23.50%29.65%30.78%16.49%7.15%6.95%8.29%4.14%5.35%7.43%8.27%9.07%8.07%7.48%8.03%9.17%12.67%13.12%8.69%7.89%10.33%9.49%9.57%8.04%6.06%
EBITDA14.67M22.00M28.74M22.32M17.06M16.54M17.82M24.22M28.49M31.05M36.46M43.02M58.31M67.18M81.29M87.90M105.42M119.42M114.84M131.27M181.65M208.69M256.59M257.51M215.26M
EBITDA Margin22.68%31.78%36.61%19.87%9.41%9.56%10.72%12.43%12.64%11.95%12.60%13.27%10.20%10.78%12.16%13.68%17.43%17.33%11.27%10.17%13.11%12.68%13.12%11.84%9.96%
Net Income7.26M13.64M15.78M11.25M7.26M7.57M7.83M10.15M13.14M17.20M20.33M24.51M33.99M38.33M44.00M50.11M62.69M70.55M73.56M79.73M103.00M118.84M141.37M135.01M84.16M
Net Income Margin11.23%19.71%20.09%10.01%4.01%4.38%4.71%5.21%5.83%6.62%7.03%7.56%5.94%6.15%6.58%7.80%10.36%10.24%7.22%6.18%7.43%7.22%7.23%6.21%3.90%
R&D---------5.78M6.50M4.89M11.69M12.30M11.25M16.02M16.83M20.48M38.06M46.97M44.02M63.89M92.44M132.14M159.09M
R&D as % of Total Revenue---------2.22%2.24%1.51%2.04%1.97%1.68%2.49%2.78%2.97%3.73%3.64%3.18%3.88%4.73%6.08%7.36%
Interest Expense2.05M1.65M1.44M698.24K545.84K692.75K319.04K548.10K2.42M2.46M2.53M2.95M2.95M6.82M9.29M7.01M4.67M4.25M4.57M9.56M17.59M21.07M26.73M26.69M25.25M
Interest Expense % of Total Revenue3.17%2.38%1.83%0.62%0.30%0.40%0.19%0.28%1.07%0.94%0.87%0.91%0.52%1.09%1.39%1.09%0.77%0.62%0.45%0.74%1.27%1.28%1.37%1.23%1.17%

Balance Sheet

Currency: CNY2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Assets103.67M115.66M126.28M293.21M312.05M305.41M335.84M357.66M359.66M383.36M401.08M418.52M443.21M649.48M658.96M1.00B1.07B1.16B1.42B1.89B2.05B2.35B2.71B2.86B3.02B
Total Liabilities48.51M46.18M41.02M46.99M61.63M49.44M76.64M87.69M77.98M89.47M92.13M90.91M92.79M247.36M224.71M225.66M239.03M286.25M473.43M805.57M867.05M1.07B1.30B1.34B1.44B
Total Equity55.16M69.48M85.26M245.50M249.76M253.93M257.35M267.12M280.22M293.14M308.52M327.18M377.48M401.68M433.93M774.15M826.71M878.10M930.24M989.25M1.07B1.16B1.27B1.35B1.40B
Cash13.92M28.52M37.30M142.66M132.29M106.28M96.78M103.92M83.66M82.65M74.90M70.72M72.97M115.25M105.43M406.74M431.07M415.05M298.16M288.47M241.83M330.69M330.65M281.38M227.72M
Total Debt26.30M24.70M23.70M11.00M18.00M14.00M36.00M35.50M34.20M37.00M38.00M39.00M40.00M142.00M108.50M95.50M95.50M86.50M106.00M327.95M334.43M508.14M637.36M674.67M784.11M
Net Debt12.38M-3.81M-13.60M-131.66M-114.29M-92.28M-60.78M-68.42M-49.46M-45.65M-36.90M-31.72M-32.97M26.75M3.07M-311.24M-335.57M-328.55M-192.16M39.48M92.60M177.45M306.71M393.29M556.39M

Cash Flow

Currency: CNY2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow--19.22M-13.19M3.39M3.82M10.14M8.03M17.44M13.83M8.43M24.00M16.94M37.17M69.50M62.12M70.28M3.64M-92.00M-9.87M91.94M138.34M127.59M160.70M10.77M
Investing Cash Flow---5.79M-17.09M-17.24M-23.25M-35.22M4.49M-32.83M-13.38M-10.17M-19.00M-26.18M-30.58M-24.85M-31.56M-44.21M-4.83M-49.26M-180.59M-129.24M-177.43M-220.68M-184.69M-184.83M
Financing Cash Flow---4.64M134.58M3.45M-6.47M-4.32M-5.40M3.13M8.07M-5.64M-7.78M-50.77M21.11M-54.56M270.25M-14.83M-32.72M789.28K192.78M13.52M141.55M76.92M-35.10M109.94M
Capital Expenditure005.97M10.18M5.24M12.65M35.19M14.08M30.25M13.29M10.26M18.98M6.30M30.85M23.37M27.41M46.21M48.64M128.36M168.63M174.18M168.92M209.02M200.66M184.84M
Free Cash Flow--13.25M-23.37M-1.85M-8.82M-25.05M-6.04M-12.80M545.39K-1.83M5.01M10.64M6.33M46.13M34.71M24.07M-45.01M-220.36M-178.50M-82.24M-30.58M-81.43M-39.96M-174.08M
Dividends Paid--3.64M762.00K3.55M3.67M4.63M6.15M2.32M4.50M6.64M8.78M13.77M15.89M21.06M20.18M14.83M23.03M27.83M22.27M42.50M31.10M54.40M43.07M50.56M
FCF to OCF--68.93%177.15%-54.44%-230.86%-246.93%-75.22%-73.40%3.94%-21.78%20.88%62.83%17.02%66.38%55.88%34.25%-1237.76%239.52%1808.55%-89.46%-22.10%-63.82%-24.87%-1616.94%
Dividend Paid to FCF--27.48%-3.26%-191.91%-41.60%-18.49%-101.73%-18.14%825.10%-361.74%175.17%129.38%251.30%45.65%58.13%61.60%-51.16%-12.63%-12.47%-51.68%-101.72%-66.80%-107.78%-29.05%

Earnings

Report DateMar 31, 2010Sep 30, 2010Dec 31, 2010Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Apr 21, 2016Aug 24, 2016Oct 27, 2016Mar 16, 2017Apr 19, 2017Aug 24, 2017Oct 28, 2017Dec 31, 2017Apr 12, 2018Jun 30, 2018Oct 27, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Aug 22, 2020Oct 30, 2020Mar 31, 2021Apr 30, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-------------------------------------------------
EPS Actual0.020.020.020.030.020.040.030.030.030.050.040.040.040.050.050.040.040.040.050.040.040.060.060.060.050.080.050.070.060.080.060.060.060.090.070.060.070.090.120.080.090.100.110.120.110.120.120.150.11
Surprise-------------------------------------------------
Timing--------------------After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-market-Pre-market--------------------

Key Statistics & Ratios

Market Cap4.31B
Enterprise Value5.70B
Trailing P/E0.00
Forward P/E40.32
Price / Sales1.44
Price / Book3.39
EPS-0.16
Book Value4.42
Revenue (TTM)3.00B
Gross Profit (TTM)885.09M
EBITDA101.23M
Profit Margin-1.59%
Operating Margin2.72%
Return on Equity-2.20%
Return on Assets-0.18%
Shares Outstanding285.46M
Shares Float167.82M
Beta-0.23
Dividend Yield0.46%
Dividend Rate0.07
Payout Ratio0.00%

Dividends

20231×
0.15May 26, 2023
20221×
0.13Jul 29, 2022
20211×
0.11Jun 18, 2021
20201×
0.08Jun 23, 2020
20191×
0.08Jun 18, 2019
20181×
0.07May 17, 2018
20171×
0.09May 19, 2017
20161×
0.05Jul 6, 2016
20151×
0.05Apr 2, 2015
20141×
0.04Jun 19, 2014
20131×
0.04May 31, 2013
20121×
0.03Jun 28, 2012
20111×
0.02Jun 20, 2011
20101×
0.02Jun 4, 2010
20091×
0.02Jul 14, 2009
20071×
0.01Jul 23, 2007
20062×
0.01Jul 17, 20060.53Mar 22, 2006
20051×
0.01Jul 15, 2005
20041×
0.01Jul 5, 2004

Stock Splits

  • May 19, 201713:10
  • Jul 6, 201613:10
  • Jun 28, 201213:10
  • Jun 4, 201013:10
  • May 30, 20083:2